Specialized Know-How and Capacity to Support Demand for Oncolytic Viruses

Few CDMOs are capable of supporting biopharma companies advancing oncolytic virus (OV) therapies toward late-stage clinical trials.

March 24th 2020

VIEW NEWS ITEM:


Our statement on COVID-19

As the world navigates the uncertainty of COVID-19, we wanted to offer some reassurance regarding the operations at Vibalogics. Our COVID-19 response team continues to.

March 24th 2020

VIEW NEWS ITEM:


Ampersand Capital Partners to Acquire Vibalogics GmbH

Vibalogics will expand capabilities to meet rapidly growing demand for development and manufacturing of complex viral products

May 29th 2019

VIEW NEWS ITEM:


Vibalogics increases capacity with a new 200L line for virus manufacturing

GERMANY-based contract development and manufacturing organization (CDMO) Vibalogics has increased its single-use bioreactor and purification capacity with a new manufacturing line to meet increasing demand for its specialist oncolytic virus and viral vector manufacturing services.

May 24th 2019

VIEW NEWS ITEM:


SIRION Biotech and Vibalogics partner to offer complete Adeno-Associated Virus (AAV) services

SIRION Biotech GmbH and Vibalogics GmbH, have signed a strategic partnership agreement designed to meet demand from gene therapy companies for a start-to-finish Adeno-Associated Virus service.

Sep 26th 2017

VIEW NEWS ITEM:


CDMO Set for Live Biological Filling Boost

GERMANY-based Vibalogics has expanded its capabilities with a new automatic vial filling line to meet increased demand from biotechnology companies for its specialist live biological manufacturing services for human and veterinary vaccines, gene therapeutics and live virus vectors.

September 3rd 2016

VIEW NEWS ITEM: